Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ethical issues and prices that are still too high for many patients.

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

MIRA's to be acquired SKNY-1 cut weight and food cravings in animals, reversed liver fat, and reduced nicotine desire—without triggering muscle loss or overstimulation.

The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this ...